<DOC>
	<DOCNO>NCT01799499</DOCNO>
	<brief_summary>This study prospective randomize open label dose range comparative study . Twenty four ( 24 ) patient NMIBC meet inclusion/exclusion criterion recruit study follow initial diagnostic cystoscopy . The investigator believe study importance several aspect : 1 . It evaluate new mode bladder instillation may bypass drawback current instillation mode . 2 . If proved effective , mode treatment might save need TURBT performance serve new mode tumor ablation . 3 . Even prove partially effective , mode treatment diminish tumor size and/or number , thus enable limited TURBT procedure . 4 . This mode treatment enable immediate medical attendance patient 's tumor recurrence without wait period ( result queues medical center ) TURBT . This might improve patient 's prognostic outcome . 5 . If experimental treatment prove well ablative effect comparison standard care know art , could translate well prophylactic effect tumor recurrence . 6 . Finding minimal , yet optimal , effective dose tumor ablation tumor recurrence prevention enable u reduce adverse effect higher drug dosage .</brief_summary>
	<brief_title>A Prospective Open Label Comparative Dose Ranging Study Evaluating Effect Pre-TURBT Intravesical Instillation Mitomycin C ( MMC ) Mixed With TC-3 Gel Patients With Non Muscle Invasive Bladder Cancer ( NMIBC )</brief_title>
	<detailed_description>Non-muscle-Invasive Bladder cancer mainly treat tumor resection ( Trans Urethral Resection - TUR ) , follow series intravesical instillation prophylactic chemotherapeutic drug Mitomycin C ( MMC ) BCG . Unfortunately , treatment approach limit due rapid dilution chemotherapeutic drug incoming urine clearance urination . TheraCoat 's core technology base reverse thermal biodegradable gel ( TC-3 Gel ) ( low viscosity cold temperature ( 5°C ) gel appearance body temperature ) drug retention urinary bladder . Prior instillation , TC-3 Gel , liquid state , mixed MMC instill bladder standard catheter . Once inside bladder , gel solidifies form drug reservoir . Upon contact urine , gel dissolve , release drug slowly finally clear bladder . Intravesical MMC instillation use TheraCoat 's gel expect increase treatment efficiency due prolongation treatment duration consequently improve bladder exposure MMC . Treatment Protocol - Immediately follow baseline cystoscopy tumor diagnosis patient undergo 6 weekly instillation follow 2-4 week heal period . 1st Follow-Up Visit ( Pre-Scheduled TURBT Visit ) : The patient undergo second cystoscopy compare baseline status . The patient followed-up period 1 year follow : 3,6,9,12 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Nucleic Acid Synthesis Inhibitors</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Patient 21 year age old . 2 . Patient sign Informed Consent Form willing able abide protocol . 3 . Single multiple tumor ( n≤7 ) 4 . Naïve Recurrent tumor 5 . No prior history HG and/or T1 and/or Tis 6 . At least one Tumor ≥ 1mm evaluate visually investigator 7 . Largest tumor diameter ≤ 30mm evaluate visually investigator 8 . Cystoscopic appearance papillary Low grade tumor 9 . The patient upper urinary tract evaluation previous year exclude urothelial carcinoma , hydronephrosis Renal Cell Carcinoma renal cancer . 10 . Good performance status ( Karnofsky performance status 70 % great ) . 11 . No active urinary tract infection confirm urine culture . 12 . If patient female childbearing potential use acceptable/effective method contraception negative pregnancy test screening . 1 . Carcinoma In Situ ( CIS ) . 2 . Over 7 lesion 3 . Lesion large 30mm diameter . 4 . `` High Grade '' urine cytology . 5 . Cystoscopic Appearance suspicious HG and/or solid and/or Tis 6. histologic result cold cup biopsy indicative HG tumor . 7 . Tumor locate prostatic urethra . 8 . Previous systemic chemotherapy pelvic radiotherapy . 9 . Pregnant breastfeeding patient . 10 . Previous treatment BCG within last 24 month . 11 . The patient least 3 month cystoscopically confirm tumorfree interval last tumor recurrence screening . 12 . Treatment intravesical chemotherapy within 3 last month . 13 . The patient has/had bladder tumor histology TCC 14 . Contraindication MMC . 15 . The patient history urinary retention PVR≥250cc bladder scan ultrasound ( PVR test may repeat 3 time ) . 16 . The patient bleed disorder screen platelet count &lt; 50X109/L . 17 . The patient screen hemoglobin &lt; 10mg/dL . 18 . The patient history Acquired Immunodeficiency Syndrome HIV positive . 19 . The patient condition concurrent severe and/or uncontrolled medical psychiatric disease ( e.g . uncontrolled diabetes , compensate congestive heart failure ( NYHA III ) , myocardial infarction within 6 month study , unstable uncontrolled hypertension active uncontrolled infection ) , accord PIs decision could compromise participation , compliance schedule visit and/or completion . 20 . The patient participate investigational protocol within past 90 day . 21 . The patient life expectancy &lt; 3 year . 22 . The patient another malignancy receive therapy malignancy last five year except : Nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma prostatic carcinoma 23 . The patient document vesicaureteral reflux indwell ureteral stent 24 . The patient tumor bladder diverticulum</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Non Muscle Invasive Bladder Cancer</keyword>
	<keyword>Intravesical instillation</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Hydrogel</keyword>
	<keyword>Reverse thermal gelation</keyword>
	<keyword>Drug retention</keyword>
	<keyword>Urinary Bladder Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histologic Type Mitomycins</keyword>
	<keyword>Mitomycin</keyword>
	<keyword>Antibiotics , Antineoplastic</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Nucleic Acid Synthesis Inhibitors</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Alkylating Agents</keyword>
</DOC>